Cargando…

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project

Extended-phase anticoagulation with direct oral Xa inhibitors (OAXI) is suggested in patients with cancer-associated venous thromboembolism (CAT). We report on patients enrolled in the MAC (Monitoring AntiCoagulants) Project, given rivaroxaban as extended-phase anticoagulation after CAT. The primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernardi, Enrico, Camporese, Giuseppe, Bortoluzzi, Cristiano, Noventa, Franco, Ceccato, Davide, Tonello, Chiara, Vohong, Stefania, Campello, Elena, Simion, Chiara, Imbalzano, Egidio, Di Micco, Pierpaolo, Callegari, Elena, Simioni, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699076/ https://www.ncbi.nlm.nih.gov/pubmed/36362880 http://dx.doi.org/10.3390/life12111725

Ejemplares similares

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
por: Bortoluzzi, Cristiano, et al.
Publicado: (2022)

MAC Project—Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol
por: Camporese, Giuseppe, et al.
Publicado: (2021)

Editorial on the Special Issue “The New Frontier of Venous Thromboembolism”
por: Di Micco, Pierpaolo, et al.
Publicado: (2023)

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
por: Poletto, Francesco, et al.
Publicado: (2022)

Special Issue “COVID-19 and Thrombosis”
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study
por: Campello, Elena, et al.
Publicado: (2020)

COVID‐19 and Venous Thromboembolism in Intensive Care or Medical Ward
por: Avruscio, Giampiero, et al.
Publicado: (2020)

Clinical Differences between COVID-19 and a COVID-Like Syndrome
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Correction: Di Micco et al. Clinical Differences between COVID-19 and a COVID-like Syndrome. J. Clin. Med. 2021, 10, 2519
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Update on the clinical use of the low-molecular-weight heparin, parnaparin
por: Camporese, Giuseppe, et al.
Publicado: (2009)

Persistently High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis
por: Spiezia, Luca, et al.
Publicado: (2023)

Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
por: Camporese, Giuseppe, et al.
Publicado: (2020)

Editorial: Vascular malformations and thrombosis
por: Di Micco, Pierpaolo, et al.
Publicado: (2023)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Diagnostic and Therapeutic Management of the Thoracic Outlet Syndrome. Review of the Literature and Report of an Italian Experience
por: Camporese, Giuseppe, et al.
Publicado: (2022)

Corrigendum: Diagnostic and therapeutic management of the thoracic outlet syndrome. Review of the literature and report of an Italian experience
por: Camporese, Giuseppe, et al.
Publicado: (2023)

Heparin and SARS-CoV-2: Multiple Pathophysiological Links
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
por: Lorenzo, Alicia, et al.
Publicado: (2022)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

Editorial Comment on the Special Issue Discussing COVID-19 and Thrombosis, Second Edition
por: Di Micco, Pierpaolo, et al.
Publicado: (2023)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study
por: Tormene, Daniela, et al.
Publicado: (2021)

Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry
por: Di Micco, Pierpaolo, et al.
Publicado: (2019)

The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report
por: Scarano, Michele, et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

POST-discharge thromboprophylaxis in patients with COVID-19: a single-center experience
por: Simion, Chiara, et al.
Publicado: (2022)

Venous thromboembolism and pregnancy
por: D’Uva, Maristella, et al.
Publicado: (2010)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia
por: Spiezia, Luca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ii17lqme3vegi453jktd62uqkr